Claims
- 1. Compounds of the formula ##STR29## in which X is hydrogen, a C.sub.1-4 -alkyl, C.sub.1-4 alkoxy, trifluoromethyl, or halogen residue,
- R.sup.1 and R.sup.2 are independently of each other a C.sub.1-4 -alkyl, C.sub.3-10 cycloalkyl, or C.sub.2-4 hydroxyalkyl residue,
- or R.sup.1 and R.sup.2 are together are a C.sub.2-6 alkylene residue in which a --CH.sub.2 -- group is optionally replaced by oxygen, nitrogen, or sulfur, n is 0 or 1, and m is 0 or a cardinal number between 1 and 5, and their pharmaceutically acceptable salts.
- 2. A compound according to claim 1, the compound being
- 1-phenyl-4-morpholinoimidazolin-2-one,
- 1-(4-methoxy)-4-piperidinoimidazolin-2-one,
- 1-(4-chlorophenyl)-4-morpholinoimidazolin-2-one,
- 1-(4-chlorophenyl)-4-piperidinoimidazolin-2-one,
- 1-(4-chlorophenyl)-4-dimethylaminoimidazolin-2-one,
- 1-(4-bromopheny)-4-morpholinoimidazolin-2-one,
- 1-(3-chlorophenyl)-4-morpholinoimidazolin-2-one,
- 1-(4-chlorophenyl)-4-hexamethyleneiminoimidazolin-2-one,
- 1-(4-chlorophenyl)-4-methylpiperazino) imidazoline-2-one,
- 1-(4-methylphenyl)-4-morpholinoimidazolin-2-one,
- 1-(4-chlorophenyl)-4-(cyclohexylmethylamino)imidazoline-2-one,
- 1-(4-fluorophenyl)-4-morpholinoimidazolin-2-one, and
- 1-benzyl-4-morpholinoimidazolin-2-one.
- 3. A process for preparing a compound of claim 1, which comprises contacting a compound of the formula. ##STR30## in which X, R.sup.1, R.sup.2, n and m have the same definitions as in claim 1, with a secondary amine of the formula HNR.sup.1 R.sup.2, at a temperature between about 50.degree. C. and about 160.degree. C.
- 4. A pharmaceutical composition containing as active ingredient at least one compound of claim 1, together with a pharmaceutical excipient, or auxiliary material.
- 5. A pharmaceutical composition containing as active ingredient at least one compound of claim 2, together with a pharmaceutical excipient or auxiliary material.
- 6. A process for treating an epileptic disorder in a host, which comprises administering to a host in need therefor an anticonvulsively effective amount of the composition of claim 4.
- 7. A process for treating an epileptic disorder in a host, which comprises administering to a host in need therefor an anticonvulsively effective amount of the composition of claim 5.
Priority Claims (1)
Number |
Date |
Country |
Kind |
195 32 668.7 |
Sep 1995 |
DEX |
|
Parent Case Info
This Application is a continuation-in-part of Ser. No. 08/708,665 filed, Sep. 4, 1996 abandoned.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
708665 |
Sep 1996 |
|